ArticleCancer gene therapy2026
Whole-genome DNA methylation analysis reveals distinct subtype characteristics in epithelial ovarian cancer.
Article in Cancer gene therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Epithelial ovarian cancer (EOC) is characterized by high mortality, insidious onset, and pronounced heterogeneity, underscoring the critical need for effective biomarkers for early detection and subtype-specific diagnosis. While DNA methylation represents a stable epigenetic marker, prior studies have largely relied on profiling techniques with limited genomic coverage and have often overlooked subtype-specific differences essential for guiding treatment decisions. To address this, we performed whole-genome bisulfite sequencing on 44 normal ovarian tissues and 89 EOC tissues encompassing all five histological subtypes, integrated with transcriptome sequencing, to comprehensively evaluate the diagnostic and prognostic utility of DNA methylation across EOC subtypes. Our analyses revealed that genome-wide methylation profiles effectively distinguished normal from tumor tissues and captured the substantial heterogeneity inherent to EOC. Differentially methylated regions (DMRs) and differentially expressed genes were enriched in immune-related processes and epithelial differentiation, aligning with the increased proportions of epithelial and immune cells identified through deconvolution analysis. Subtype-specific DMRs further implicated hormonal pathways in endometrioid (EC) and clear cell (CCOC) carcinomas, and linked mucinous ovarian cancer (MOC) to fluid regulation. Integrative analysis of DMRs and cellular composition indicated that epithelial cells in high-grade serous (HG), low-grade serous (LG), and EC tumors most closely resembled fallopian tube, ovarian, and endometrial epithelial cells, respectively, whereas MOC and CCOC epithelial cells showed similarity to gastrointestinal and renal epithelia. Moreover, weighted gene co-expression network analysis identified epithelia-associated DMRs that achieved up to 90% specificity for subtype classification in internal validation and demonstrated prognostic relevance in independent public datasets. In conclusion, the subtype-specific DNA methylation markers identified in this study accurately reflect the distinct histological features of each EOC subtype and hold promise for application in subtype classification and prognosis prediction, thereby providing a scientific foundation for future clinical interventions in EOC.
Identifiers
42850375What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.